CFTR

CFTR
Emw · CC BY-SA 3.0 · source
Name	Cystic fibrosis transmembrane conductance regulator
Uniprot	P13569
Gene	CFTR
Location	Chromosome 7q31.2

CFTR CFTR is a membrane-bound ATP-gated ion channel expressed in epithelial cells that regulates chloride and bicarbonate transport. Discovered through genetic linkage studies in the 1980s, CFTR mutations underlie cystic fibrosis and contribute to other pathologies; ongoing research connects CFTR to ion homeostasis, mucosal immunity, and epithelial repair mechanisms.

Introduction

CFTR was identified by investigators during positional cloning efforts associated with the Cystic Fibrosis Foundation and mapped using techniques developed at institutions such as Cold Spring Harbor Laboratory and University of Michigan. Early clinical correlations emerged from cohorts assembled at Great Ormond Street Hospital and population studies reported by teams collaborating with the National Institutes of Health. Landmark papers appeared in journals linked to editorial boards at the Nature Publishing Group and Science (journal), shaping translational programs at pharmaceutical companies including Vertex Pharmaceuticals.

Structure and Molecular Function

The CFTR protein is a member of the ATP-binding cassette family characterized by two membrane-spanning domains and two nucleotide-binding domains; structural insight derives from cryo-electron microscopy datasets produced at facilities like EMBL and Max Planck Institute. ATP binding and hydrolysis at the nucleotide-binding domains control gating, an allosteric process modeled by groups at Cold Spring Harbor Laboratory and Stanford University. Regulatory control involves a unique regulatory (R) domain phosphorylated by protein kinase A pathways first delineated in studies from Harvard Medical School; phosphorylation alters interactions with scaffolding proteins such as NHERF1 characterized in work from Yale University. CFTR mediates transepithelial ion gradients crucial for mucociliary clearance studied in airway models at Johns Hopkins University and pancreatic duct models developed at University of California, San Francisco.

Genetics and Regulation

The canonical CFTR gene locus on Chromosome 7 (human) exhibits allelic heterogeneity with hundreds of variants cataloged by consortia including the Clinical and Functional TRanslation of CFTR (CFTR2) project and databases maintained by the European Molecular Biology Laboratory. The ΔF508 (deletion of phenylalanine at position 508) variant was first reported by researchers affiliated with the Hospital for Sick Children, Toronto and remains the most prevalent mutation in populations sampled by the 1000 Genomes Project and Human Genome Project datasets. Regulatory elements upstream and intronic enhancers discovered in studies from the Broad Institute interact with transcription factors characterized at EMBL-EBI; epigenetic modulation involving histone modifications was reported in collaborative work with the Wellcome Trust centers. Population genetics analyses performed by teams at University of Oxford and University of Cambridge have explored founder effects and selective hypotheses across European, Ashkenazi Jewish, and African cohorts curated by the World Health Organization.

Clinical Significance and Diseases

Pathogenic CFTR variants cause cystic fibrosis, a multi-system disease managed in centers such as Boston Children's Hospital and Great Ormond Street Hospital. Clinical manifestations include recurrent pulmonary infections with organisms documented by microbiology groups at Centers for Disease Control and Prevention, exocrine pancreatic insufficiency treated by protocols from the American Gastroenterological Association, and male infertility due to congenital bilateral absence of the vas deferens first described in case series from Mayo Clinic. CFTR dysfunction is also implicated in pancreatitis cohorts studied at Mount Sinai Hospital and in chronic rhinosinusitis clinics at Cleveland Clinic. Modifier gene studies from consortia including the International Cystic Fibrosis Gene Modifier Consortium have linked outcomes to loci reported by teams at University of Toronto and McGill University.

Diagnostic Testing and Biomarkers

Newborn screening programs coordinated by public health agencies such as the Centers for Disease Control and Prevention and the European Centre for Disease Prevention and Control use immunoreactive trypsinogen assays combined with CFTR targeted mutation panels developed in laboratories at Johns Hopkins University and University College London. Sweat chloride testing protocols standardized by the Cystic Fibrosis Foundation remain a diagnostic gold standard, while next-generation sequencing panels implemented at genomic centers like the Broad Institute and Wellcome Sanger Institute allow comprehensive variant detection. Functional assays including nasal potential difference and intestinal current measurements were refined in clinical research units affiliated with UCLA and Karolinska Institutet and serve as biomarkers in therapeutic trials overseen by regulatory agencies such as the Food and Drug Administration.

Therapeutic Approaches and Drug Development

Therapeutics target folding, trafficking, gating, and downstream inflammation. Small-molecule modulators pioneered by Vertex Pharmaceuticals—potentiators like ivacaftor and correctors such as lumacaftor and tezacaftor—emerged from collaborations with academic groups at University of Texas and clinical trials coordinated through cooperative groups like the Cystic Fibrosis Foundation Therapeutics (CFFT). Gene therapy approaches tested in trials sponsored by entities including Genzyme and consortia with NIH funding explore viral and non-viral delivery, while CRISPR-based genome editing strategies have been advanced by laboratories at MIT and Broad Institute. Adjunctive therapies addressing infection and inflammation draw on antimicrobial stewardship guidelines from World Health Organization and pharmacology research from University of California, San Diego. Ongoing phase 3 and real-world effectiveness studies reported by networks such as the European Cystic Fibrosis Society continue to refine precision medicine algorithms.

Category:Membrane transport proteins